Well Thomson Reuters puts M&A activity up nearly 40% on last year and likely to hit an all time high in 15/16. So that's positive. It will depend on where you are doing it of course - healthcare and pharma are the hot tickets - big pharma cant risk the low ROI of blockbuster drugs R&D anymore so they are acquiring smaller biotechs to buy in innovation, healthcare providers and payers are consolidating partly to find economies of scale, partly to maintain margins in value based pricing. This shows no signs of abating. Of course, the VCs and PEs also continue to be a strong bet - everyone is getting hurt by China, so less cash calls means those VCs still making investments (and there are many) are either in the for longer haul (so want to know what IT they'll inherit and in what state) or using their reserves to invest at lower prices, so more emphasis then on value creation from eg consolidations etc. There's gold in them there hills.
